<DOC>
	<DOCNO>NCT02766686</DOCNO>
	<brief_summary>ProtoChoice-P prospective multicenter trial evaluate proton therapy patient suffer prostate cancer . Primary aim study decrease moderate severe genito-urinary intestinal side effect ( Common Terminology Criteria Adverse Events ( CTCAE ) 4.0 grade 2 high ) use proton therapy . Secondary endpoint contain assessment quality life , biochemical recurrence recurrence free survival well overall survival economic comparison photon proton therapy .</brief_summary>
	<brief_title>Preference-based Comparative Study Definitive Radiotherapy Prostate Cancer With Protons</brief_title>
	<detailed_description>The hypothesis study 7.5 % decrease combine genito-urinary intestinal side effect 15 % photon therapy 7.5 % use proton . With alpha 0.05 80 % power therefore necessary treat 131 patient proton detect difference . With estimate drop-out rate 10 % 146 patient recruit proton arm . As randomization photon proton therapy possible multicenter set proton facility available patient treat photon prospectively match proton counterpart . Stratification criterion include : Age , high dose volume , androgen deprivation , history surgery , obstructive disease , increase risk rectal bleeding , socio-economic criterion use rectal balloon radiotherapy . Comparison primary endpoint restrict patient without irradiation lymphatic drainage .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>life expectancy ≥ 10 year adenocarcinoma prostate confirm punch biopsy locally limit locally advanced adenocarcinoma without evidence distant metastasis i.e . T13b N01 M0 stagerelated indicated neoadjuvant / adjuvant androgen deprivation possible ( neoadjuvant ≤ 6 month ) good general condition ( ECOG performance status 0 1 ) marker seed implantation irradiation ( optional ) possibility Imageguided Radiation Therapy ( IGRT ) CT adequate compliance followup write informed consent distant metastases previous radiotherapy lesser pelvis previous concomitant malignant disease except impact treatment followup prostate cancer participation another clinical study , 's exclude study protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>proton radiotherapy</keyword>
	<keyword>photon radiotherapy</keyword>
</DOC>